Interaction of helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in gastric and duodenal ulcers

Helicobacter

Volumn 15, Issue 4, 2010, Pages 239-250

  Venerito, Marino ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Helicobacter pylori; nonsteroidal anti inflammatory drugs; peptic ulcer

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; LICOFELONE; METRONIDAZOLE; MONOCLONAL ANTIBODY KI 67; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; TETRACYCLINE;

APOPTOSIS; ARTICLE; BLEEDING; CELL PROLIFERATION; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DUODENUM ULCER; EPITHELIUM CELL; ERADICATION THERAPY; GASTROSCOPY; HELICOBACTER INFECTION; HUMAN; INFECTION PREVENTION; LOW DRUG DOSE; MICROCIRCULATION; NICK END LABELING; PEPTIC ULCER BLEEDING; POLYMORPHONUCLEAR CELL; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK; SECONDARY PREVENTION; STOMACH ACID SECRETION; STOMACH BLOOD FLOW; STOMACH MUCOSA LESION; STOMACH PARIETAL CELL; STOMACH PH; STOMACH ULCER; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; DUODENAL ULCER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DUODENAL ULCER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH ULCER;

HELICOBACTER PYLORI;

EID: 77954832395     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00762.x     Document Type: Article

References (68)

1. Hunt R, Bazzoli F. Review article: Should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004 19 : 9 16.
2. Cryer B, Spechler SJ. Peptic ulcer disease. Sleisenger and Fortran′s Gastrointestinal and Liver Disease 8th ed.
3. Tummala S, Keates S, Kelly CP. Update on the immunologic basis of Helicobacter pylori gastritis. Curr Opin Gastroenterol 2004 20 : 592 597.
4. Kauffman G. Aspirin-induced gastric mucosal injury: lessons learned from animal models. Gastroenterology 1989 96 : 606 614.
5. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. The Lancet 2009 374 : 1449 1461.
6. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997 350 : 975 979.
7. Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003 17 : 799 805.
8. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002 51 : 329 335.
9. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998 352 : 1016 1021.
10. Pilotto A, Di Mario F, Franceschi M, et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000 14 : 1077 1082.
11. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. New Engl J Med 2001 344 : 967 973.
12. Bianchi Porro G, Parente F, Imbesi V, et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. Gut 1996 39 : 22 6.
13. Chan FK, Sung JJ, Suen R, et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998 12 : 1201 1205.
14. Levine RA, Nandi J, King RL. Nonsalicylate nonsteroidal antiinflammatory drugs augment prestimulated acid secretion in rabbit parietal cells. Investigation of the mechanisms of action. Gastroenterology 1991 101 : 756 765.
15. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008 134 : 306 323.
16. El-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995 109 : 681 691.
17. El-Omar EM, Oien K, El Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997 113 : 15 24.
18. Naylor GM, Gotoda T, Dixon M, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 2006 55 : 1545 1552.
19. Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987 1 : 89 96.
20. Xiao F, Furuta T, Takashima M, et al. Effects of cyclooxygenase-2 inhibitor on gastric acid secretion in Helicobacter pylori-infected C57BL/6 mice. Scand J Gastroenterol 2001 36 : 577 583.
21. Feldman M, Colturi TJ. Effect of indomethacin on gastric acid and bicarbonate secretion in humans. Gastroenterology 1984 87 : 1339 1343. (Pubitemid 15201433)
22. Feldman M, Shewmake K, Cryer B. Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans. Am J Physiol Gastrointest Liver Physiol 2000 279 : G1113 20.
23. Cryer B, Feldman M. Effects of very low-dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999 117 : 17 25.
24. Venerito M, Treiber G, Wex T, et al. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther 2006 23 : 1225 1233.
25. 2 levels. Scand J Gastroenterol 2008 43 : 801 809.
26. Sung JJY. Should we eradicate Helicobacter pylori in non-steroidal anti-inflammatory drug users? Aliment Pharmacol Ther 2004 20 : 65 70.
27. Leung WK, To KF, Chan FK, et al. Interaction of Helicobacter pylori eradication and non-steroidal anti-inflammatory drugs on gastric epithelial apoptosis and proliferation: implications on ulcerogenesis. Aliment Pharmacol Ther 2000 14 : 879 885.
28. Zhu GH, Yang XL, Lai KC, et al. Nonsteroidal antiinflammatory drugs could reverse Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells. Dig Dis Sci 1998 43 : 1957 1963.
29. Laine L, Tacheuki K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008 135 : 41 60.
30. Guth PH. Current concepts in gastric microcirculatory pathophysiology. Yale J Biol Med 1992 65 : 677 688.
31. Konturek JW, Dembinski A, Konturek SJ, et al. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998 114 : 245 255.
32. McCarthy CJ, Crofford LJ, Greenson J, et al. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999 94 : 1218 1223.
33. Brzozowski T, Konturek PC, Konturek SJ, et al. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 2005 56 : 33 55.
34. Elizalde JI, Mendez A, Gomez J, et al. Gastric mucosal blood flow changes in Helicobacter pylori infection and NSAID-induced gastric injury. Helicobacter 2003 8 : 124 131.
35. Maxis K, Delalandre A, Martel-Pelletier J, et al. The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase- activating protein. Arthritis Res Ther 2006 8 : R181.
36. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007 357 : 1841 1854.
37. Bias P, Buchner A, Klesser B, et al. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 2004 99 : 611 618.
38. Whittle BJ. Nitric oxide and the gut injury induced by non-steroidal anti-inflammatory drugs. Inflammopharmacology 2003 11 : 415.
39. Fiorucci S, Santucci L, Gresele P, et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003 124 : 600.
40. Uno K, Kato K, Atsumi T, et al. Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007 293 : G1004 12.
41. Lazaraki G, Kountouras J, Metallidis S, et al. Helicobacter pylori infection upregulates endothelial nitric oxide synthase expression and induces angiogenesis in gastric mucosa of dyspeptic patients. Eur J Gastroenterol Hepatol 2008 20 : 441 449.
42. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006 130 : 188 206.
43. Wallace JL, McKnight W, Miyasaka M, et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol 1993 265 : G993.
44. Ernst P. Review article: the role of inflammation in the pathogenesis of gastric cancer. Aliment Pharmacol Ther 1999 13 : 13 8.
45. Wilson KT, Crabtree JE. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007 133 : 288 308.
46. Crowe SE, Alvarez L, Dytoc M, et al. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 1995 108 : 65.
47. Sharma SA, Tummuru MK, Miller GG, et al. Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro. Infect Immun 1995 63 : 1681 1687.
48. Venerito M, Kuester D, Wex T, et al. The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype - a link to gastric carcinogenesis. Cancer Lett 2008 270 : 218 228.
49. Mori N, Wada A, Hirayama T, et al. Activation of intercellular adhesion molecule 1 expression by Helicobacter pylori is regulated by NF-kappaB in gastric epithelial cancer cells. Infect Immun 2000 68 : 1806 1814.
50. Taha AS, Angerson W, Nakshabendi I, et al. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs, influence of age, smoking, ulceration and Helicobacter pylori. Aliment Pharmacol Ther 1993 7 : 41 5.
51. Hudson N, Balsitis M, Filipowicz B, et al. Effect of Helicobacter pylori colonization on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993 34 : 748 751. (Pubitemid 23185097)
52. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990 259 : G462 7.
53. Santucci L, Fiorucci S, Giansanti M, et al. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut 1994 35 : 909 915.
54. Asako H, Kubes P, Wallace J, et al. Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 1992 262 : G903 8.
55. Yoshida N, Takemura T, Granger DN, et al. Molecular determinants of aspirin-induced neutrophil adherence to endothelial cells. Gastroenterology 1993 105 : 715 724.
56. Taha AS, Dahill S, Moran C, et al. Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. Gastroenterology 1999 116 : 251 258.
57. Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004 126 : 980 988.
58. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAIDinduced ulcer management (OMNIUM) study group. N Engl J Med 1998 338 : 727 734.
59. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med 1998 338 : 719 726.
60. El-Omar EM. The importance of IL-1β in Helicobacter pylori associated diseases. Gut 2001 48 : 743 747.
61. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996 334 : 1018 1022.
62. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 781. (Pubitemid 46854190)
63. Schmassmann A, Zoidl G, Peskar BM, et al. Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice. Am J Physiol Gastrointest Liver Physiol 2006 290 : G747 56.
64. Gilster J, Bacon K, Marlink K, et al. Bismuth subsalicylate increases intracellular Ca2+, MAP-kinase activity, and cell proliferation in normal human gastric mucous epithelial cells. Dig Dis Sci 2004 49 : 370 378.
65. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009 104 : 728 738.
66. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008 103 : 2890 2907.
67. Fischbach W, Malfertheiner P, Hoffmann JC, et al. S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology. Z Gastroenterol 2009 47 : 1230 1263.
68. Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009 29 : 481 496.